GO
Loading...

Biotechnology

More

  • Biotech Stocks Immune to Mandate?     Thursday, 28 Jun 2012 | 11:30 AM ET

    A look at the impact of the Supreme Court's ruling on biotech stocks, with James Greenwood, BIO CEO.

  • Obama's Legacy In the Balance     Wednesday, 27 Jun 2012 | 7:11 PM ET

    Could Obamacare be a "legacy-killer" for Obama? David Goodfriend, former Clinton White House official, and Michael Medved, radio talk show host, share their opinions.

  • Obamacare Fate With the Supremes     Wednesday, 27 Jun 2012 | 7:00 PM ET

    CNBC's John Harwood reports on the anticipation for the ruling on Obamacare tomorrow; and Edward Klein, Author of "The Amateur," weighs in. "If the Supreme Court rules against Obamacare, I think it will be a grievance blow to [Obama's] presidency," says Klein.

  • Obamacare: Portfolio Impact     Wednesday, 27 Jun 2012 | 6:20 PM ET

    Discussing the impact the ruling of Obamacare could have on the economy, with Senator John Barrasso (R-WY); Ron Kruszewski, Stifel Nicolaus & Company CEO; and Michael Farr, Farr, Miller & Washington.

  • Biotech & Drug Stocks: Scotus Ruling Impact     Wednesday, 27 Jun 2012 | 5:15 PM ET

    The biotech sector is up more than 1 percent today, and discussing what investors can expect after tomorrow's health care reform ruling, with ISI's biotech and pharmaceuticals major analyst Mark Schoenebaum. "If tomorrow the whole bill is struck down, technically, earnings and revenue estimates for all of biotech and all of pharma companies are going to go up," says Schoenebaum.

  • Arena Surges on FDA Approval     Wednesday, 27 Jun 2012 | 5:15 PM ET

    Shares of Arena Pharmaceuticals spiked on news the FDA approved its anti-obesity drug, with the Fast Money traders; and discussing how tomorrow's ruling on the health care reform could impact the biotech sector, with Mark Schoenebaum, ISI.

  • Cramer Interviews Seattle Genetics CEO Tuesday, 5 Jun 2012 | 6:50 PM ET

    The "Mad Money" host spoke with the CEO of Seattle Genetics about the safety of the biotech space.

  • Cramer’s One-on-One with Immunogen CEO Monday, 4 Jun 2012 | 6:20 PM ET

    Daniel Junius, CEO of Immunogen, discusses drugs the company is developing.

  • Metals ETFs Attracting Safe Haven Crowd Tuesday, 29 May 2012 | 4:05 PM ET

    Investors who jumped into U.S. Treasurys and the dollar during the latest flare-up of the EU crisis appear to have expanded into gold and other metals, according to a new report.

  • Winning Equity ETFs During May EU Crisis Tuesday, 29 May 2012 | 12:42 PM ET

    A few sectors have managed to gain ground during the past three weeks, and retail investors who took advantage of the right ETFs have something to show for it.

  • How Microprocessors Are Reinventing the Prosthesis Tuesday, 29 May 2012 | 11:22 AM ET

    Faced with more service members returning without limbs from Iraq and Afghanistan, scientists, the government and private-sector companies are using new materials, tools and techniques to create sophisticated prostheses for amputees.

  • There is a great chance that Sirius XM Radio’s stock will hit $1.65 within the next several sessions — in other words, this is bound to get worse before it gets better.

  • 5 Stocks Under $10 Poised for Breakouts Thursday, 17 May 2012 | 12:50 PM ET

    Here’s a look at several under-$10 stocks that look poised to potentially trade higher from current levels.

  • Jobs for Loners Tuesday, 8 May 2012 | 4:44 PM ET
    In the immortal words of Barbra Streisand, people who need people are the luckiest people in the world. But what about the rest of us? We don’t all have what it takes to be gregarious, and outgoing, and one’s ability to be sociable, or lack thereof, can affect the type of employment one ends up taking.The extroverted have a bevy of jobs that let them press the flesh. There are sales, management, life coaching, and any number of other jobs that demand constant interaction with others. On the othe

    Many jobs that let reserved types work in solitude offer poor salaries and unchallenging work. But there are other careers that are stimulating, well-paying and require little human contact.

  • Cramer's Top Dividend Stocks 2012 Monday, 30 Apr 2012 | 9:27 AM ET
    Whether or not the stock market continues to rally, Jim Cramer recommends investors seek the protection of stocks with serious dividends. After all, if the stock market falls and the economy worsens, dividend-paying stocks will pay investors to wait until things get better. The "Mad Money" host especially likes “accidental high-yielders” — the stocks with small payouts that wouldn’t ordinarily offer high yields. Because of downward pressure in the markets, which has hurt their share prices, thos

    We pulled together a list of Cramer's favorite dividend plays. Read on and pick one or two for your portfolio. They could offer just the kind of defense that you need.

  • Spotlight: Energy Monday, 23 Apr 2012 | 1:05 PM ET
    Wind farm in Evia, Greece

    There are too many options but no one solution to the energy problem. Our needs are many. The current alternative energies — solar, wind, biofuels, nuclear and geothermal — all have limitations, but they're worth it until something better comes along.

  • Sanofi-Aventis CEO: We've Been Quick to Move Friday, 13 Apr 2012 | 10:50 AM ET

    Sanofi-Aventis has been quick to move before its patents on bestselling products expired, said CEO Chris Viehbacher.

  • Cramer's Growth Play on Celgene     Thursday, 12 Apr 2012 | 6:45 PM ET

    Mad Money's Cramer runs through a ten-point checklist to see if Celgene is in a position to deliver growth to investors.

  • The Trade Behind Allergan's Pullback, Cramer     Thursday, 12 Apr 2012 | 6:25 PM ET

    Cramer's analysis on Allergan shows that it's a high-quality stock that can be bought into weakness.

  • Celgene Riding Molecular Biology 'Revolution': CEO Thursday, 12 Apr 2012 | 5:31 PM ET
    E. Coli

    Investors are suddenly hot for biotechnology, and that helps Celgene, CEO Robert Hugin told CNBC Thursday.